Cognitive and emotional symptoms are recognized as integral to the BBS phenotype. While not at all universally present, neurodevelopmental and behavioral features are common across BBS genotypes and contribute significantly to the disease burden.
Cognitive and Emotional Profile
Most individuals with BBS present with mild intellectual disability or borderline cognitive performance, though this varies by subtype. Performance IQ often exceeds verbal IQ, with non-verbal problem-solving relatively preserved in many cases presented in existing literature. Some studies found that individuals with BBS1 mutations typically show less cognitive impairment than those with BBS10 or BBS12, which are more frequently associated with moderate intellectual disability.
Behavioral dysregulation is another core feature, often present independently of IQ. Anxiety and affective symptoms are common, sometimes in the absence of overt depression. Autism spectrum features, including restricted interests and impaired social communication, have also been widely reported. These features may not correlate directly with the degree of cognitive impairment, suggesting partially distinct mechanisms.
Underlying Mechanisms
The neurobiological basis is currently (2025) poorly understood, but several converging lines of evidence implicate ciliary dysfunction in neuronal development and hypothalamic signaling, altered mitochondrial dynamics and calcium handling that contribute not only to metabolic dysregulation but potentially also to mood and arousal circuits, and elevated ER stress and altered mTOR signalling.
Management
While no targeted therapy exists for neuropsychiatric symptoms in BBS, individualized neuropsychological evaluation and early developmental support are essential. Selective pharmacologic interventions may be used cautiously to address ADHD or mood symptoms, while behavioral therapy and social skills training benefit many children with autism-like features.
We highlight a number of compounds whose safety and pharmacological profiles are well-established through extensive research in both human and animal studies. These agents have demonstrated mechanisms of action that intersect with known disease pathways in Bardet-Biedl Syndrome (BBS)—including mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and disrupted cellular signaling. While these compounds have not yet been tested specifically in humans with BBS, preclinical evidence and mechanistic plausibility suggest that they may offer symptom-modifying potential in certain contexts. It is important to emphasize that their use in BBS remains experimental and investigational, and any consideration may also be guided by clinical oversight and individualized assessment.
Learnings and Emotions – simple summary
- To follow shortly
🔷 If you have experience with any of these compounds and their effects in BBS, we would love to hear from you on: info [ @ ] bbs-hub.org